Veradigm (MDRX) Status update summary

Strategic initiatives and operational progress

• Launched the Reset, Recover, Reignite plan to reset strategy, regain market leadership, and drive profitable growth.

• Discontinued six low-revenue products and reallocated capital to growth areas with near- and long-term potential.

• Expanded AI initiatives, including new applications for revenue cycle services and product development.

• Flattened organizational structure, increased manager span, and reduced workforce by 15% in 2025.

• Rolled out enterprise-wide objectives and key results, achieving 100% adoption in a new ERP system.

Financial performance and outlook

• 2025 revenue estimated at $584–$589 million, down 1% from 2024's $590–$595 million; Provider segment down 2%, Payer and Life Sciences flat.

• Profitability softened in 2025 due to Atlas-related IT and accounting expenses.

• Net cash at year-end 2025 was $120 million, down from $294 million in 2024, mainly due to debt repayment and transaction expenses.

• Debt at December 31, 2025 was $75 million, reflecting a new senior secured term loan maturing in 2030.

• Legal and accounting fees expected to decrease in 2026 as audit and remediation work winds down.

Capital and liquidity actions

• $159 million net outflows from debt financing, including repurchase of convertible notes and new term loan.

• $14 million outflows for prior acquisitions and $62 million for transaction and other expenses.

• $31 million net inflows from investment portfolio activity and $62 million net inflows from operational items.